Ramipril for COVID-19: real-time analysis

Download Image

Post

c19early.org

Ramipril for COVID-19

1 study with 114 patients

Serious outcome risk

Ramipril

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Ramipril studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−144%

Mortality (1)−144%

RCTs (1)−144%

Late (1)−144%

00.511.5+

← Ramipril
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Ramipril is an oral small molecule angiotensin-converting enzyme (ACE) inhibitor that blocks the renin-angiotensin-aldosterone system (RAAS).


Aug 24 2023	Huang et al., Advances in Therapy, doi:10.1007/s12325-023-02618-7	Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Aug 24 2023	144% higher mortality (p=1), 289% higher ventilation (p=1), 289% higher ICU admission (p=1), and 144% lower hospital discharge (p=1). RCT 114 non-critically ill COVID-19 patients in the USA showing no significant differences with ramipril treatment.